- Home
- TRVI vs RZLT Comparison
TRVI vs RZLT Comparison
Compare TRVI & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVI
- RZLT
- Stock Information
- Founded
- TRVI 2011
- RZLT 2010
- Country
- TRVI United States
- RZLT United States
- Employees
- TRVI N/A
- RZLT N/A
- Industry
- TRVI Biotechnology: Pharmaceutical Preparations
- RZLT Biotechnology: Pharmaceutical Preparations
- Sector
- TRVI Health Care
- RZLT Health Care
- Exchange
- TRVI Nasdaq
- RZLT Nasdaq
- Market Cap
- TRVI 341.4M
- RZLT 292.0M
- IPO Year
- TRVI 2019
- RZLT N/A
- Fundamental
- Price
- TRVI $3.76
- RZLT $4.87
- Analyst Decision
- TRVI Strong Buy
- RZLT Strong Buy
- Analyst Count
- TRVI 8
- RZLT 8
- Target Price
- TRVI $9.31
- RZLT $11.63
- AVG Volume (30 Days)
- TRVI 659.4K
- RZLT 349.3K
- Earning Date
- TRVI 11-06-2024
- RZLT 02-11-2025
- Dividend Yield
- TRVI N/A
- RZLT N/A
- EPS Growth
- TRVI N/A
- RZLT N/A
- EPS
- TRVI N/A
- RZLT N/A
- Revenue
- TRVI N/A
- RZLT N/A
- Revenue This Year
- TRVI N/A
- RZLT N/A
- Revenue Next Year
- TRVI N/A
- RZLT N/A
- P/E Ratio
- TRVI N/A
- RZLT N/A
- Revenue Growth
- TRVI N/A
- RZLT N/A
- 52 Week Low
- TRVI $1.27
- RZLT $0.92
- 52 Week High
- TRVI $4.68
- RZLT $6.19
- Technical
- Relative Strength Index (RSI)
- TRVI 48.03
- RZLT 49.47
- Support Level
- TRVI $3.63
- RZLT $4.47
- Resistance Level
- TRVI $4.06
- RZLT $4.98
- Average True Range (ATR)
- TRVI 0.30
- RZLT 0.33
- MACD
- TRVI -0.09
- RZLT -0.01
- Stochastic Oscillator
- TRVI 12.21
- RZLT 38.10
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About RZLT Rezolute Inc. (NV)
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.